TICKERNERD
Menu
OMDAOMDAHealthcare · Health Information Services

OMDA Stock Forecast: Omada Health, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$20
+0.35% on the day

The 12 Wall Street analysts covering Omada Health, Inc. hold a median 12-month price target of $28 — +41.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 17 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
83 / 100
Median analyst target
$28
Analysts covering
12
Revenue$87.8M+43.1% y/y
Operating income$3.5M
Net income$5.3M
Free cash flow$2.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.8%
1M
−16.5%
YTD
+25.7%
1Y
−12.0%
From 52W high
−26.0%
From 52W low
+81.3%
$11
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OMDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Omada Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Revisions
86
Issuance
79
Quality
71
Accruals
68
Momentum
54
Size
43
Value
37
Volatility
17

Growth (89): Sales and profits are climbing, and climbing faster than before.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OMDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OMDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26OMDAHigh $35Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $22Median $28High $35

The green dot is the last close — the median target sits +41.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Sept 2026BarclaysMaintainsOverweight$25 → $27
11 Sept 2026BTIGReiteratesBuy$35
11 Sept 2026NeedhamReiteratesBuy$28
14 Aug 2026CitizensMaintainsMarket Outperform—
14 Aug 2026CitizensMaintainsMarket Outperform$27 → $32
14 Aug 2026JP MorganMaintainsOverweight$26 → $30
14 Aug 2026JP MorganMaintainsOverweight—
12 Aug 2026BairdMaintainsNeutral$15 → $25
12 Aug 2026BairdMaintainsNeutral—
10 Aug 2026BTIGMaintainsBuy—
10 Aug 2026BTIGMaintainsBuy$30 → $35
3 Aug 2026BarclaysMaintainsOverweight—
3 Aug 2026BarclaysMaintainsOverweight$20 → $25
21 July 2026Canaccord GenuityMaintainsBuy$24 → $28
21 July 2026Canaccord GenuityMaintainsBuy—
20 July 2026CitizensMaintainsMarket Outperform$21 → $27
20 July 2026CitizensMaintainsMarket Outperform—
17 July 2026BTIGInitiatesBuy$30
17 July 2026BTIGInitiatesBuy—
22 June 2026Morgan StanleyReiteratesOverweight$30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OMDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Omada Health, Inc. returned −12.0% against +17.0% for the S&P 500, dividends included.

OMDA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26OMDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OMDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+33.5%
Analysts raising
5
Analysts cutting
0
Fundamentals

Omada Health, Inc. (OMDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.7×

Cheaper than 25% of US stocks

Price / sales
3.9×

Cheaper than 31% of US stocks

Price / book
4.7×

Cheaper than 22% of US stocks

EV / EBITDA
180.9×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
43.1%

Higher than 84% of US stocks

Earnings growth (YoY)
43.1%

Higher than 72% of US stocks

Gross margin
72.6%

Higher than 85% of US stocks

Operating margin
4.0%

Higher than 53% of US stocks

Net margin
1.4%

Higher than 51% of US stocks

Returns & dividend
Return on equity
1.8%

Higher than 47% of US stocks

Return on assets
−0.1%

Higher than 43% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Omada Health, Inc. (OMDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Omada Health, Inc. has a market value of $1.2B and an enterprise value of $982.4M.

  • Revenue in the twelve months to 30 June 2026: $309.8M. The latest quarter grew 43.1% year on year.

  • Net income over the same four quarters: $4.3M, a 1.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.05.

  • Free cash flow in the twelve months to 30 June 2026: $17.1M, after $5.6M of capital spending.

  • Shares outstanding: 60.6M.

  • Trailing P/E: 30.7×; forward P/E: 35.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Omada Health, Inc. employs 946 people — $327K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Sept 2026

Data provided by Twelve Data

Peers

OMDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
OMDAOmada Health, Inc.$1.2B
83
GDRXGoodRx Holdings, Inc.$1.2B
78
TDOCTeladoc Health, Inc.$1.1B
66
CERTCertara, Inc.$1.4B
56
OMCLOmnicell, Inc.$1.5B
96
HSTMHealthStream, Inc.$866.0M
95
SOPHSOPHiA GENETICS SA$715.6M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Omada Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OMDA news & analysis

Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript

Seeking Alpha · 11 Sept 2026neutral

Omada Health, Inc. held an Analyst/Investor Day, and Seeking Alpha published the transcript of the event, covering management's discussion with analysts and investors. The transcript provides a record of the company's presentations and remarks from the occasion.

Why it matters — A transcript of the Analyst/Investor Day offers OMDA watchers direct access to management's commentary and the company's stated outlook as presented to investors.

Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day

GlobeNewsWire · 10 Sept 2026neutral

Omada Health announced it will present updated long-term financial targets at its inaugural Investor Day, held today at the Four Seasons Hotel in New York. The virtual-first, between-visit healthcare provider is set to outline these targets to investors at the event.

Why it matters — Omada watchers will learn the company's updated long-term financial targets for the first time at its inaugural Investor Day, which could frame its growth outlook.

Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada's GLP-1 Program

GlobeNewsWire · 9 Sept 2026positive

Omada Health announced a new independent cost savings model for its GLP-1 program. GlobalData published a report estimating greater disease reduction and higher cumulative gross medical cost savings—up to $11,142 per member over five years—compared to standard care.

Why it matters — A third-party analysis quantifying the clinical and economic value of Omada's GLP-1 program could support the company's market positioning and value proposition.

Insider Alert: Omada Health CEO Sean Duffy Sells 31,457 Shares

The Motley Fool · 9 Sept 2026neutral

Omada Health CEO Sean Duffy sold 31,457 shares at a weighted average price of $23.37 per share, for a transaction value of approximately $735,150. The sale represented about 2% of his total equity stake before the filing and 8% of his prior direct position.

Why it matters — A CEO insider sale is closely watched by Omada Health investors as a signal of leadership sentiment regarding the company's stock.

Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings

Seeking Alpha · 12 Aug 2026positive

Omada Health reported strong Q2 results with 43% revenue growth, margin expansion, and positive adjusted EBITDA, driven by product expansion in diabetes and hypertension and improved customer lifetime value through multi-program adoption.

Why it matters — The results indicate Omada's growth is increasingly translating into earnings, with channel partnerships and AI initiatives supporting scalable operations and better unit economics.

FAQ

Frequently asked questions about OMDA stock

What is the OMDA stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Omada Health, Inc. have a median 12-month price target of $28, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OMDA stock a buy right now?

Of the 12 analysts covering Omada Health, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omada Health, Inc. 83 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OMDA?

As at 17 Sept 2026, Omada Health, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will OMDA stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +41.2% from the last close, and Ticker Nerd's factor model ranks Omada Health, Inc. 83 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OMDA stock forecast for 2030?

No analyst covering Omada Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.

How has OMDA stock performed over the past year?

Omada Health, Inc. returned -12.0% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Omada Health, Inc. do?

Omada Health, Inc. Common Stock represents Omada Health, a digital health company focused on virtual care for chronic condition prevention and management.

What is the latest news on OMDA?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript". Omada Health, Inc. held an Analyst/Investor Day, and Seeking Alpha published the transcript of the event, covering management's discussion with analysts and investors. The transcript provides a record of the company's presentations and remarks from the occasion.

Company

About Omada Health, Inc.

Omada Health, Inc. Common Stock represents Omada Health, a digital health company focused on virtual care for chronic condition prevention and management. The company provides evidence-based programs that combine coaching, connected devices, and digital tools to support people living with prediabetes, diabetes, hypertension, weight management needs, and musculoskeletal conditions. Omada Health works primarily with employers, health plans, pharmacy benefit managers, and health systems, helping them offer scalable care delivery outside traditional clinic settings. Its platform centers on ongoing, between-visit support designed to improve adherence, encourage healthier behaviors, and integrate with broader population health initiatives. Based in South San Francisco, California, Omada Health plays a notable role in the healthcare technology market by delivering virtual-first services that address long-term, high-prevalence conditions through personalized, technology-enabled care.

CEO Mr. Sean P. Duffy · 946 employees · United States · https://www.omadahealth.com